A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Study summary

This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAtezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody and Placebo Comparator

Plus 5 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Early-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 9, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?117 U.S. locations

Locations may change over time.

Who runs it?Hoffmann-La Roche

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 3
Sponsor: Hoffmann-La Roche
Interventions being studied: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Drug: Placebo Comparator; Drug: Nab-paclitaxel; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Gemcitabine

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Early-stage or resectable→

Treatment approach

Immunotherapy→Chemotherapy→Supportive or behavioral care→

Study topics

Before surgery (neoadjuvant)→After surgery (adjuvant)→Survivorship and quality of life→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging system
Evaluation by an attending thoracic surgeon to confirm eligibility for an R0 resection with curative intent
Adequate pulmonary and cardiac function to undergo surgical resection
Measurable disease as defined by RECIST v1.1
Adequate hematologic and end organ function
Negative HIV test at screening
Negative for active HBV and HCV at screening
Adequate tissue for PD-L1 IHC assessment

Reasons someone may not be able to joinExclusion criteria

NSCLC with histology of large cell neuroendocrine carcinoma or sarcomatoid carcinoma
Mixed NSCLC and small cell lung cancer histology
Any prior therapy for lung cancer
Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome
Non-squamous NSCLC histology with activating ALK and EGFR mutation
Pregnant or lactating women
History of autoimmune disease
History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or evidence of active of active pneumonitis on screening chest Computed Tomography (CT) scan
Prior treatment with cluster of differentiation 137 (CD137) agonist or immune checkpoint blockade therapies, anti-programmed-death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibody
Severe infection within 4 weeks prior to randomization
Significant history of cardiovascular disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Arizona OncologyTucson, Arizona
USC Norris Cancer CenterLos Angeles, California
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of OrangeOrange, California
UC Davis Cancer CenterSacramento, California
Scripps ClinicSan Diego, California
National Jewish HealthDenver, Colorado
Rocky Mountain Cancer CenterDenver, Colorado
Georgetown UniversityWashington D.C., District of Columbia
Washington Cancer InstituteWashington D.C., District of Columbia
Illinois Cancer CarePeoria, Illinois
University of MichiganAnn Arbor, Michigan
Barbara Ann Karmanos Cancer InstituteDetroit, Michigan

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 9, 2026. Always confirm current availability with the study team.

View original record ↗